Stay connected! Share and follow:

Leukaemia CARE Careline

We're here to talk | 24-hours a day

08088 010 444

FREE from landlines & most major mobile networks

New CML treatment approved for Scottish NHS Patients

written by

Leukaemia Care, Charity

  • SMC 2

It was announced yesterday that the Scottish Medicines Consortium (SMC) has accepted bosutinib for use within NHS Scotland. Bosutinib is marketed by Pfizer as Bosulif®.

Bosutinib is an oral, once daily tyrosine kinase inhibitor (TKI). TKIs work by blocking or ‘inhibiting’ a protein called Bruton’s tyrosine kinase (BTK), which stimulates the growth of cancer cells. Current treatments for chronic myeloid leukaemia (also known as chronic myelogenous leukaemia or CML) include the first generation TKI imatinib and the second generation TKIs nilotinib and dasatinib.

The recommendation of the SMC, following a re-submission under the ultra-orphan medicine process, states that bosutinib is accepted for use within NHS Scotland for the “treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.”

For more information on the SMC decision, please click here.

The SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of bosutinib. The advice also takes account of the views from a Patient and Clinician Engagement (PACE) meeting, which was held with patient group representatives (including Leukaemia CARE) and clinical specialists to consider the added value of bosutinib, as an ultra-orphan medicine, in the context of NHS Scotland.

Monica Izmajlowicz, Chief Executive of Leukaemia CARE said: “We welcome this decision by the Scottish Medicines Consortium as a step forward in the treatment of CML patients within NHS Scotland. We are pleased to see that the new PACE framework has been effective in ensuring that patients who need it can access this treatment.”

For further information on chronic myeloid leukaemia (CML), please click here.